Immune cell therapy with or without lenvatinib for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system, Infections clinical trials.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced liver cancer that cannot be removed by surgery or other local treatments, and it must have gotten worse after at least one round of standard drug treatment.
- You must have chronic hepatitis B virus infection, and your liver function must still be good enough (Child-Pugh class A) to tolerate the treatment.
- You must have a specific protein pattern on your cells (called HLA) that matches the experimental cells used in this trial.
- You must be in generally good physical condition (able to do light work or be up and about) and not have brain metastases or other serious uncontrolled medical conditions.
- You must not have recently had other cancer treatments, and you must be willing to stop them for a period before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This Phase 2 study tests whether combining three treatments—lenvatinib, tislelizumab, and a liver-directed chemotherapy approach (HAIC)—can shrink advanced hepatocellular carcinoma. It may help people whose cancer is stage C and hasn’t been treated before.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.